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We investigated the effect of a new dextran derivative, phenylacetate carboxymethyl benzylamide dextran (NaPaC), on epidermoid
carcinoma A431 cells secreting a large quantity of angiogenic factor, vascular endothelial growth factor (VEGF). In vitro, NaPaC
inhibited the proliferation of A431 cells (IC50¼5mM). Also, NaPaC decreased the binding of radiolabelled VEGF165 to endothelial
cells (IC50¼0.2mM). In vivo, we explored the effects of NaPaC (15mgkg
 1) on A431 xenograft growth starting the drug
administration at the time of tumour cell inoculation (early treatment) and 1 week later, when tumours were well established (late
treatment). Early treatment was more efficient on tumour inhibition (70% vs control) than late treatment (50% vs control). Early and
late NaPaC-treatment increased the aponecrosis in tumour by 70 and 30%, respectively. Whatever treatment, NaPaC inhibited the
intratumour endothelial cell density in the same manner. In contrast, vessel area was decreased only when NaPaC was injected early
(35%). These results show that NaPaC has a potent inhibitory effect, dependent on treatment outset, on epidermoid carcinoma
growth associated with an intratumour microvascular network diminution and an aponecrosis increase. As this drug is nontoxic at
efficient dose, it offers interesting perspectives for the therapy of malignant lesions.
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Angiogenesis, the formation of new blood vessels from established
vessels, occurs under a variety of normal and pathological
conditions. Also, it is a requisite for tumour growth and metastasis
dissemination (Blood and Zetter, 1990; Ramanujan et al, 2000).
The delivery of blood-borne nutrients to the tumour cells is
essential for their survival and spread. Thus induction of
angiogenesis was observed to precede the development of invasive
tumours (Weidner et al, 1991).
We recently demonstrated in vitro that phenylacetate carbox-
ymethyl benzylamide dextran (NaPaC) inhibited the secretion of
growth factors from breast cancer cells and prevented the action of
growth factors by interacting with them (Di Benedetto et al, 2002).
In particular, we showed that NaPaC formed complexes with
vascular endothelial growth factor (VEGF165), which is a specific
mitogenic factor for endothelial cells. Vascular endothelial growth
factor is the best-characterised VEGF-A form the expression of
which has been correlated, temporally and/or spatially, with the
onset of angiogenesis in a variety of tumours including lung
(Senger et al, 1986), breast (Krantz et al, 1999), ovarian (Shen et al,
2000) and colon cancer (Cascinu et al, 2000).
In this report, we investigated the effect of NaPaC on the in vitro
and in vivo growth of epidermoid carcinoma A431 cells that
secrete a large amount of VEGF (Myoken et al, 1991). First, we
explored in vitro if NaPaC could inhibit the A431 cell proliferation
and prevent the binding of VEGF165 on tumour and endothelial
cells. Then in vivo, we assessed the effects of NaPaC on the A431
tumour growth, cell death and microvascular system development
in xenografts implanted in nude mice. Since angiogenesis occurred
as specific spatiotemporal events (Mori et al, 1999) and since
distinct antiangiogenic drugs have been shown to be effective at
different stages of tumorigenesis (Bergers et al, 1999), we have
studied and compared the tumours from animals treated with
NaPaC starting at early or late stage of xenograft development.
MATERIALS AND METHODS
Dextran derivative preparation
New dextran derivative, phenylacetate carboxymethyl benzylamide
dextran (Figure 1), named NaPaC, was synthesised by Biodex
Laboratory (Supplier) (Levallois-Perret, France) performing a
statistical esterification of carboxymethyl benzylamide dextran
with phenylacetic acid (Avramoglou et al, 2001). After purification
by ultrafiltration (purity 498%) and lyophilisation, the chemical
composition or degree of substitution (ds) of NaPaC was
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sdetermined by acidimetric titration and elementary analysis of
nitrogen. The composition of NaPaC was: 0ds for dextran, 0.67ds
for carboxymethyl and 0.39ds for benzylamide and a phenylace-
tate ds of 0.35. The calculated average molecular weight of NaPaC
mer was 264.1gU
 1. Absolute molecular weight was calculated
multiplying the average molecular weight by the number of units
(247). This calculation leads to MW: 77 607gmol
 1.
Cell culture
Human epidermoid carcinoma A431 cells and human umbilical
vein endothelial cells (HUV-EC) were purchased from American
Tissue Culture Collection (Rockville, MD, USA). They were
routinely grown in DMEM (Life Technologies, Inc., Gaithersburg,
MD, USA), supplemented with 10% FCS, 2mML -glutamine, 1mM
sodium pyruvate, 50Uml
 1 penicillin and 50mgml
 1 streptomy-
cin (all obtained from Life Technologies, Inc.), at 371Ci na5 %
CO2-humidified atmosphere.
Cell growth assays
A431 cell growth was assessed using the MTT-microculture
tetrazolium assay (Mosmann, 1983). Briefly, the cells (4 10
3)
were incubated in 2% FCS–DMEM for 24h and then treated with
NaPaC at different concentrations for 72h. Then, the cells were
washed with phosphate buffer saline (PBS) and incubated with
0.1ml of MTT (2mgml
 1) for 4h.
Binding competition assay
HUV-EC and A431 cells were grown until 80% confluence in 24-
well tissue culture plates (Falcon, Strasbourg, France). After an
overnight incubation in serum-free medium and two washings
with ice-cold binding buffer (PBS, 0.2% gelatine), cells were
incubated at 41C for 2h in 0.3ml of binding buffer containing 7pM
125I-VEGF165 (Amersham Pharmacia Biotech, Orsay, France) in the
presence or absence of NaPaC at increasing concentrations
(0–24mM). Incubation was arrested by gently removing the
medium and washing the cell monolayer three times with ice-
cold binding buffer. The radioactivity bound to cells was measured
in gamma counter (LKB 1261 Multigamma) after cell lysis in 0.3ml
of 0.5 N NaOH for 30min. Nonspecific binding was determined in
the presence of an excess (5nM) of unlabelled VEGF165 (R&D
Systems, Abingdon, UK). For the Scatchard plot analysis
(Scatchard, 1986), binding was accomplished with increasing
concentrations of unlabelled VEGF165 (0–5000pM) and 7pM
125I-
VEGF165 in the presence or absence of NaPaC at IC50. Each curve
was analysed according to the Scatchard procedure or by fitting a
logistic curve (Graph Pad Software). All analyses were performed
twice and carried out in triplicate.
Xenografts in nude mice
All in vivo experiments were carried out with ethical committee
approval and met the standards required by the UKCCCR
guidelines (Workman et al, 1998). A431 cells (1 10
5) were
inoculated subcutaneously (s.c.) near the right mammary fad pad
of 4-week-old athymic nude mice (nu/nu, n¼40) (Harlan
Laboratory, Gannat, France). Animals were kept in a tempera-
ture-controlled room on a 12:12 light–dark schedule with food
and water ad libitum. Phenylacetate carboxymethyl benzylamide
dextran was administrated following two protocols starting at early
or late stage of xenograft development. In the first treatment, the
administration of NaPaC (15mgkg
 1, n¼10) begun at the time of
A431 cell inoculation: the tumour cells were injected s.c. in 0.1ml
of NaPaC solution. In the control group (n¼10), the A431 cells
were injected in 0.1ml of 0.9% NaCl. The drug or 0.9% NaCl
solution was administrated twice a week for 5 weeks. In the other
protocol (late), the NaPaC treatment started 1 week after cell
inoculation when palpable tumours have been developed. It is
noteworthy that these tumours were observed in 20 out of 20
animals. Then, mice were arbitrarily placed in control (n¼10) and
NaPaC-treated group (n¼10). Phenylacetate carboxymethyl ben-
zylamide dextran (15mgkg
 1) was injected in 0.1ml of 0.9% NaCl
s.c. near the tumour, twice a week for 5 weeks. Control received
0.1ml of 0.9% NaCl. Tumour volumes were calculated as
previously described (Di Benedetto et al, 2001). In our experiment,
we have used NaPaC at doses previously reported to be efficient on
breast cancer cells xenografted in nude mice (Di Benedetto et al,
2002).
Endothelial cell staining in tumour sections
Tumour specimens were fixed with a solution of paraformaldehyde
(4%) and included into paraffin using standard procedure.
Routinely, 5mm sections were stained in haematoxylin and eosin.
For immunohistochemical studies, the sections were deparaffi-
nised and rehydrated. Endogenous peroxidase was inactivated with
3% H2O2. After washing in TBS (0.05 M Tris, 1.5 M NaCl, pH 7.6),
the tumour sections were preincubated with 10% normal goat
serum for 1h at room temperature. Endothelial cells were
specifically labelled with GSL-1 isolectin B4 (Vector Laboratories,
Burlingame, CA, USA). The GSL-1 lectin binds specifically to
galactosyl residues and thus labels the mouse endothelial cells
(Alroy et al, 1987). The sections were labelled for 1h with the 1:50
diluted GSL-1 isolectin at room temperature, then incubated with
goat antibody against GSL-1 isolectin B4 (1:400 dilution, Vector
Laboratories) for 30min, washed with TBS and incubated with
biotinylated rabbit anti-goat immunoglobulins (1:400 dilution;
Dako, Glostrup, Denmark) for 20min in a moist chamber at room
temperature. After three washes with TBS, samples were incubated
with streptavidin–biotin peroxidase (LSAB kit; Dako) for 10min
using 3-amino-9-ethylcarbazole (AEC) chromogen, giving a red
staining. Finally, slides were washed in water and counterstained
with haematoxylin.
Microvessel analysis in tumour sections
Intratumour number of endothelial cells per tumour section area
(endothelial cell density) was determined using a point-counting
grid over the GSL-1-labelled cells (96 points in the grid
corresponding to an area of 1.02mm
2 on the picture) (Weibel,
1979). For each tumour, 10 randomly selected nonserial sections
were studied. For each section, 10 fields containing exclusively
viable tumour cells, as indicated by the haematoxylin staining,
were selected randomly for analysis. Using a Reichter-Jung
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Figure 1 Structure of NaPaC.
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s(Polivar, Austria) microscope, each tumour was scanned at  100
magnification to select the regions with the most intense
vascularisation following the criteria previously defined (Weidner
et al, 1991). For each region, at least two pictures were taken at
 250 magnification. The highest number of endothelial cells
identified within any  250 field (1.02mm
2) was taken into
account. The coefficient of variation (SD) was used to assess the
variability of counts divided by field number of the same tumour.
Mean intratumour endothelial cell numbers per area in the various
tumours were compared using Student’s t-test. To estimate the
area of vessels in tumour section, the lumens bordered with at least
one GSL-1-stained endothelial cell were counted using the point-
counting grid. The intratumour vessel area was expressed as the
ratio of determined counts to total points of grid (96) according to
Weibel method (Weibel, 1979). Thus, vessel area represents the
fraction of the total tissue area occupied by the wall or lumen and
reflects the overall number and size of vessels. For all statistical
analyses, the level of significance was set at 0.05.
Cell death detection and quantification in tumour sections
Tumour sections (5mm) were deparaffinised and rehydrated, then
analysed for cell death DNA fragmentation using TumorTACS kit
(R&D Systems, Abington, UK). Intratumour aponecrotic cells were
counted using a point-counting grid over the apoptotic cells as
described above for endothelial cells. For each tumour section, 10
different fields were selected for analysis.
Statistical analysis
Multiple statistical comparisons were performed using ANOVA
in a multivariable linear model. Some statistical analyses
were performed using the Mann–Whitney t-test. Po0.05 was
considered statistically significant.
RESULTS
NaPaC inhibits the in vitro proliferation of epidermoid
carcinoma A431 cells
We have recently shown that NaPaC has an antiproliferative effect
on various breast cancer cells (Di Benedetto et al, 2002). Here, we
demonstrated that NaPaC is able to inhibit the in vitro growth of
epidermoid carcinoma A431 cells in a dose-dependent manner
(Figure 2). After a 72h incubation, the maximal inhibitory effect
(70%) was achieved in the presence of 48mM NaPaC (P¼0.03). The
NaPaC concentration inducing 50% of maximal inhibition (IC50)
was 5mM.
Phenylacetate carboxymethyl benzylamide dextran
inhibits VEGF165 binding to A431 cells
As we recently showed that NaPaC forms a complex with VEGF165
(Di Benedetto et al, 2002) and as A431 cells secrete high amounts
of VEGF165 (Myoken et al, 1991) we tested, here, the effect of
NaPaC on the binding of VEGF to A431 cells (Figure 3).
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Figure 2 Phenylacetate carboxymethyl benzylamide dextran inhibits the
A431 cell proliferation. Cells were incubated for 72h in the absence or
presence of NaPaC at various concentrations. Cell growth was assessed
using MTT-assay as described in Materials and Methods. Each point
represents the mean 7s.d. of three independent experiments.
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Figure 3 NaPaC inhibits the VEGF165 binding to A431 cells. (A) Cells
were incubated with a fixed concentration of [
125I]VEGF165 (7pM) in the
absence or presence of NaPaC at various concentrations (0.0375–24mM).
(B, C) Scatchard analysis was performed using 7pM [
125I]VEGF165 and
unlabelled VEGF165 at various concentrations in the absence (B)o r
presence (C) of 0.3mM NaPaC (IC50).
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sPhenylacetate carboxymethyl benzylamide dextran inhibited the
binding of VEGF165 to A431 cells in a concentration-dependant
manner with an IC50 of 0.3mM (Figure 3A). The binding of VEGF165
was completely abolished by 6mM NaPaC. For Scatchard analysis,
the cells were incubated with radiolabelled VEGF165 (7pM) and
unlabelled VEGF165 at increasing concentrations in the presence
(Figure 3C) or in the absence (Figure 3B) of 0.3mM NaPaC (IC50).
In control conditions (in the absence of NaPaC), two classes of
binding sites were observed. The higher affinity class is
characterised by a Kd of 100pM and the lower affinity population
by a Kd of 1200pM. The addition of 0.3mM (IC50) NaPaC did not
significantly affect the affinity of the first class sites, but induced
the disappearance of the low-affinity population (Figure 3C). This
can be explained by the fact that NaPaC at IC50 formed a complex
only with a fraction of VEGF165, thus decreasing the concentration
of the remaining available growth factor below the level required
for binding to low-affinity sites. At higher concentration (6mM),
NaPaC was able to block VEGF165 binding to high-affinity sites
since no specific binding was observed (Figure 3A). These
experiments clearly showed that NaPaC prevented the VEGF165
binding to A431 cells involving, at least in part, interactions with
the growth factor.
Phenylacetate carboxymethyl benzylamide dextran
inhibits the VEGF165 binding to human umbilical vein
endothelial cells
Phenylacetate carboxymethyl benzylamide dextran inhibited the
binding of VEGF165 to human umbilical vein endothelial cells
(HUV-EC) in a concentration-dependant manner with an IC50 of
0.2mM (Figure 4). The binding of VEGF165 was completely
abolished by 6mM NaPaC. Scatchard analysis revealed in control
conditions (in the absence of NaPaC), two classes of binding sites
as observed by others (Soker et al, 1996; Li et al, 2001). The higher
affinity class is characterised by a Kd of 355pM and the lower
affinity population by a Kd of 1000pM. The addition of 0.2mM of
NaPaC (IC50) did not significantly affect the affinity of the first
class sites, but induced the disappearance of the low-affinity
population (data not shown). The disappearance of high-affinity
sites was achieved in the presence of drug at a higher
concentration (6mM). Like for A431 cells (above), these experi-
ments clearly showed that NaPaC inhibited the VEGF165 binding to
HUV-EC cells probably by forming a complex with the growth
factor.
Phenylacetate carboxymethyl benzylamide dextran
inhibits the A431 xenograft growth more efficiently
when administrated early
We evaluated the A431 xenograft growth when NaPaC adminis-
tration begun simultaneously with tumour cell inoculation (early
treatment, Figure 5, black symbols) and when NaPaC injection, at
the same dose and for the same period of 5 weeks, started 1 week
after A431 cell inoculation, when palpable tumours appeared (late
treatment, Figure 5, white symbols). Whatever treatment, early or
late, a significant inhibition of xenograft growth was observed at
the 5th week of NaPaC administration. However, early NaPaC
treatment reduced the tumour growth by 70% as compared to
control (P¼0.0067), whereas late administration of the drug
inhibited the A431 tumour growth by 50% (P¼0.0011). Early
administration of NaPaC was not able to affect the A431 tumour
uptake. The chronic administration of NaPaC (15mgkg
 1) to A431
xenograft-bearing mice, twice a week for 5 weeks, did not cause
signs of toxicity. The body weight of mice was not affected. No
diarrhoea, infection, weakness or lethargy was stated. All of the 40
studied mice were alive at the end of treatments.
Phenylacetate carboxymethyl benzylamide dextran induces
cell death in tumour more effectively when administrated
early
In both, early (Figure 6B) and late (Figure 6C), NaPaC-treated
tumours, we observed a more intense brown staining of the nuclei
of apoptotic cells as well as a more diffused brown staining of the
cytoplasm and the nuclei of necrotic cells as compared to control
(Figure 6A). Since the difference between the staining of necrotic
and apoptotic cells was difficult to distinguish, we counted all
brown-stained cells. This statement is in agreement with our recent
observations that, in breast cancer xenografts, NaPaC induced
rather aponecrosis (Di Benedetto et al, 2002) described by Formigli
et al (2000) than classical apoptosis. In the early treated tumours,
large regions of necrosis were observed (Figure 6B) and the
number of aponecrotic cells per area was increased by 70% as
compared to control (Po0.0001). In the case of late treatment with
NaPaC, the density of aponecrotic cells was increased by 30%
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Figure 4 NaPaC inhibits the VEGF165 binding to HUV-EC endothelial
cells. Cells were incubated with a fixed concentration of [
125I]VEGF165
(7pM) in the absence or presence of NaPaC at various concentrations
(0.01–24mM)
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Figure 5 A431 tumour growth inhibition induced by early and late
administrations of NaPaC in nude mice. Early treatment (black symbols)
was performed by a simultaneous s.c. inoculation of A431 cells (1 10
5)a t
day 0 and NaPaC (15mgkg
 1). Late s.c. treatment (white symbols) with
NaPaC (15mgkg
 1) began 1 week after tumour uptake, when tumours
were well established (¼100mm
3). NaPaC was injected twice a week for
5 weeks for both early and late treatment. Control groups received 0.1ml
of 0.9% NaCl for the same period. Each point represents the mean of
tumour volume (mm
3) 7 s.d. (n¼10).
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regions were diminished as compared to early treated tumours
(representative photos shown in Figure 6).
Effect of early- and late-administrated NaPaC on the
microvascular system of A431 tumour
As we recently demonstrated that NaPaC inhibited in vitro the
growth of human endothelial cells (HUV-EC) (Di Benedetto et al,
2002) and since we showed, in this paper above, that NaPaC
competes with VEGF165 for the binding to endothelial cells, we
evaluated the drug effects on microvessel development in A431
tumours (Figure 7). We attempted to operate on vessel network in
xenograft at two different stages of its formation by early
(Figure 7B) and late (Figure 7D) administration of NaPaC.
The number of endothelial cells per tumour tissue area (1mm
2)
was decreased by 50% (P¼0.006) after early NaPaC administra-
tion as compared to control (no treated) and 30% (P¼0.045) after
late treatment as compared to corresponding no treated control
(Figure 8A). When early treated tumours were compared to late
treated ones this parameter was statistically similar. Concerning
the fraction of the total tissue area occupied by the wall and/or
lumen of vessel (vessel area), NaPaC was inefficient when used
lately as compared to control (Figure 8B), whereas it has an
inhibitory effect (35%, P¼0.014) when injected early. Thus,
NaPaC, administrated early, is able to affect the endothelial cell
number and vessel area whereas NaPaC, injected late, alters only
the first parameter.
DISCUSSION
In this paper, we showed the antiproliferative, antiangiogenic and
aponecrotic action of a new dextran derivative, NaPaC, on fast
growing xenografts of A431 cells derived from an aggressive
epidermoid carcinoma. A431 cells are known to secrete a large
quantity of VEGF (Myoken et al, 1991), a potent angiogenic factor.
We recently demonstrated that NaPaC interacted with VEGF165 by
forming a complex and inhibited the proliferation of endothelial
cells stimulated by VEGF165 (Di Benedetto et al, 2002). Here, we
demonstrated, in addition, that NaPaC inhibited the binding of
VEGF165 to its specific receptors on human endothelial cells. In the
light of these NaPaC properties, we attempted to inactivate locally
VEGF165 secreted by A431 cells at two different steps of xenograft
development: by early administration of NaPaC, starting at tumour
cell inoculation; and late treatment, beginning 1 week later when
tumours were well established. Thus, we could operate on vessel
network formation at two different stages. Since the tumour
growth was largely demonstrated to be dependent on angiogenesis
(Folkman, 1995; Carmeliet and Jain, 2000), we explored the impact
of tumour vasculature evolution on the A431 xenograft growth.
In the case of both early and late treatments, NaPaC strongly
inhibited the A431 tumour growth. It is well established now that
tumour growth can be affected by tumour cell proliferation,
tumour cell death and angiogenesis. Concerning cell proliferation,
NaPaC was shown, here, to inhibit the in vitro A431 growth. This
action could involve, at least in part, the decreasing VEGF165
binding to A431 cells as reported in this study. However, like
Melnyk et al (1996), we were not able to evidence a VEGF
dependence of A431 cell growth in vitro (data not shown) probably
because of the high quantity of the secreted endogenous VEGF
(Myoken et al, 1991). In vivo, we found that early NaPaC
administration for 5 weeks was significantly more efficient than
late one. Nevertheless, for both treatments, the A431 tumour
uptake was observed at the same time after cell inoculation and the
difference in growth rate of tumours only became significantly
apparent after 4 weeks. In the light of these observations, the
difference in effect of early and late NaPaC treatment cannot be
explained considering only direct inhibitory effect of NaPaC on
tumour cell proliferation.
In relation to tumour growth inhibition, we observed an
increase in aponecrotic cell density in tumours. Indeed, the cell
death was more important in early NaPaC-treated tumours than in
late treated ones. Although, in our experimental conditions, we
cannot distinguish the tumour and endothelial cells undergoing a
death, it is clear that difference observed above is related to
variations in the death of rather tumour cells than endothelial
ones. The argument supporting this idea is that endothelial cell
density was decreased in early and late treated tumours in the
same manner. We recently reported that NaPaC induced in vitro
Figure 6 Phenylacetate carboxymethyl benzylamide dextran induces the
cell death in early and late treated A431 tumours. Cell death of untreated
(A) and early (B) or late (C) treated tumours was assessed by terminal
deoxynucleotidyl transferase-mediated nick-end labelling using Tumour
TACS kit. Necrotic area was marked with asterisks. Representative
aponecrotic cells were marked with arrows.
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sthe aponecrosis of breast cancer MCF-7ras cells (Di Benedetto et al,
2002) arguing for a possible direct aponecrotic effect of NaPaC on
A431 cells. Nevertheless, in vivo, it is also likely that cell death was
generated in tumour, at least in part, by oxygen deprivation of
tissue owing to angiogenesis inhibition.
We showed in this report that both early and late treatments
with NaPaC decreased, to the same extent, the endothelial cell
density. In contrast, the vessel area, reflecting the overall number
and/or size of vessels, was reduced in early treated tumours,
whereas it was unchanged in late treated xenografts as compared
to control. Thus, the vessel morphology in early and late treated
tumours was different. These results showed that NaPaC, injected
early, prevents the vessel enlargement and/or the increase in vessel
number, these modifications being observed in late (1 week
delayed) treated tumours as well as in control ones. Thus, a first
week of A431 xenograft development, in the absence of NaPaC, is
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Figure 8 Quantification of endothelial cell density and vessel area in
early and late NaPaC-treated tumours. (A) The GSL-1 lectin-stained
endothelial cells per mm
2 of tumour area (endothelial cell density) and (B)
the fraction of the total tissue area occupied by the wall or/and lumen
(vessel area) was determined as described in Materials and Methods. Each
column represents the mean 7 s.d. (n¼10). *Po0.05 vs control.
Figure 7 Effects of NaPaC on A431 tumour microvessel network.
Endothelial cells were stained in early (A) and late (C) treatment controls,
and in early (B) and late (D) NaPaC-treated tumours using GSL-1 lectin.
Microvessel lumens in panels were indicated with asterisks. Magnification
used was  250. The representative AEC-stained endothelial cells (red)
are indicated with arrows.
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Interestingly, even 5 weeks NaPaC treatment was not able to affect
these changes. The morphological transformations of intratumour
vessels were recently described (Eberhard et al, 2001, Izumi et al,
2002, Leenders et al, 2002; Ryschich et al, 2002). In particular, it
was observed that the early event of tumour angiogenesis consists
in dilating the existing vessels prior to their sprouting (Eberhard
et al, 2001; Leenders et al, 2002). This finding is in agreement with
our observation that the vessel area was higher in late treated
tumours, when NaPaC administration started 1 week after
xenograft cell implantation, than in early treated ones, where
NaPaC acted at the beginning of intratumour vasculature
formation. As VEGF, produced in large amounts by A431 cells,
has also vasodilating activity (Dvorak et al, 1999), it is possible that
NaPaC administrated early was able to inactivate, at least in part,
this growth factor and consequently to prevent vessel dilation.
Since vessels are present even in the early treated tumours, it could
be that A431 cells surround and co-opt, immediately after
inoculation, the existing subcutaneous vessels as it was described
in the case of non-small-cell-lung carcinoma (Pezzela et al, 1997)
and melanoma (Leenders et al, 2002). Moreover, NaPaC seems to
have no effect, administrated early or late, on this phenomenon.
However, we cannot discard that in our experimental model the
formation of neo-vessels occurs very early and that NaPaC is not
able to inhibit it completely.
Altogether, our results showed that NaPaC inhibited the A431
tumour growth acting on both endothelial and tumour cells. The
extent of this effect was dependent on the outset of NaPaC
treatment. Since the period of NaPaC action on A431 cell
proliferation was the same (5 weeks) and since the endothelial
cell density was decreased in the same manner in both early and
late treated tumours, the most probable is that the difference in
tumour growth inhibition was because of changes in intratumour
vascular network leading to the increase in tumour cell death
observed above. Altogether, our data indicate that A431 xenograft
model can be used to study the impact of vascular network in
tumour growth and to screen potential antiangiogenic agents.
In conclusion, we demonstrated that NaPaC potently inhibits
fast-growing epidermoid carcinoma by acting on tumour cells and
intratumour endothelial cells whatever the state of xenograft
development. Nontoxic at efficient doses, NaPaC provides inter-
esting clues for therapies of solid tumours preventing the vascular
network evolution in malignant lesions, thus inhibiting the rapid
expansion from small tumours to late-stage tumours. Moreover, its
direct inhibitory action on tumour cell proliferation argues for its
usefulness in late-stage tumour treatment.
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